| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 03 Nov 2026 |
Form 4: Bjorkquist Jeanette M, PFO and PAO
Received 3,840 shares as a grant or award · Sold 727 shares ($14.3K) |
| 03 Nov 2026 |
Form 4: White Nicole S, Chief Manufacturing Officer
Received 13,705 shares as a grant or award · Sold 2,593 shares ($50.9K) |
| 03 Nov 2026 |
Form 4: Delaney William E Iv, Chief Scientific Officer
Received 13,705 shares as a grant or award |
| 03 Nov 2026 |
Form 4: Gaggar Anuj, Chief Medical Officer
Received 13,705 shares as a grant or award · Sold 2,593 shares ($50.9K) |
| 03 Nov 2026 |
Form 4: Okazaki Jason A, Director
Received 38,380 shares as a grant or award · Sold 6,202 shares ($122K) |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 20 Aug 2026 | S-8 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 |
8-K/A: Results of Operations and Financial Condition
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Completion of Acquisition or Disposition of Assets
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 04 Aug 2026 | SCHEDULE 13G/A |
| 18 Jun 2026 |
Form 4: Bjorkquist Jeanette M, PFO and PAO
Sold 29 shares ($674) |
| 05 Jun 2026 |
Form 4: Gaggar Anuj, Chief Medical Officer
Received 14,000 shares as a grant or award |
Loading...